Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Net Income
Bottom-line profit after all expenses, interest, and taxes.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income remains negative
Q3 FY2026 net income was -$94.23M, compared with -$73.93M a year earlier. Trailing-twelve-month net income was -$359.43M.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 13 analysts of -$313.36M (-3.3%) for the fiscal year ending Dec 2026, a step up from the -65.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$94.23M-12.6% QoQ
- Last fiscal yearDec 2025
- -$303.27M-65.9% YoY
- LTMSep 2026
- -$359.43M-31.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.5% | -40.6% | -13.1 pp |
| 1 year | -65.9% | -3.3% | +62.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (303.27M) USD
- Year-over-year change
- -65.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (303.27M) | -65.9% |
| FY2024 | 2024-12-31 | (182.82M) | -48.3% |
| FY2023 | 2023-12-31 | (123.28M) | +42.4% |
| FY2022 | 2022-12-31 | (214.03M) | -28.1% |
| FY2021 | 2021-12-31 | (167.06M) | — |
Net Income vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 net income of -$359.43M is the 8th highest of the 10 companies compared; the peer median is -$109.89M.
- Its year-over-year change of -31.6% is the 7th highest of 10, against a peer median of +13.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $702.5M | +64.1% | +45.8% | 19.0% | |
| LTM Sep 2026 | $362.23M | +38.7% | — | 30.1% | |
| LTM Dec 2025 | -$39.95M | +14.1% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$107.28M | -34.6% | — | 536.4% |
| LTM Jun 2026 | -$109.89M | -270.4% | — | 13.2% | |
| LTM Jun 2026 | -$191.64M | +22.4% | — | 24.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$222.39M | +13.8% | — | — |
| LTM Sep 2026 | -$359.43M | -31.6% | — | — | |
| LTM Sep 2026 | -$428.73M | -40.0% | — | — | |
| LTM Jun 2026 | -$511.45M | -6.8% | — | 14191.2% | |
| Peer median (excluding PRAX) | -$109.89M | +13.8% | +45.8% | 27.4% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| Weighted Avg Shares | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Weighted Avg Shares (Diluted) | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.